Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review

Table 1 Palliative radiotherapy for hepatocellular carcinoma metastatic sites

Ref.	Metastatic lesion treated	Patient (n)	Total dose, fraction size	Response	Median survival
Yamashita et al[122] (Retro)	LNs	28	46-60 Gy, 2Gy	PR: 64%; CR: 18%	13 mo
Zeng et al[29] (Retro)	LNs	62	40-60 Gy, 2 Gy	PR: 37.1%; CR: 59.7%	9.4 mo
He et al[121] (Retro)	Bone	30	8-60 (median 40) Gy	96.7% pain relief	8.6 mo
Seong et al[26] (Retro)	Bone	51	12.5-50 (median 30) Gy	73% pain relief	5 mo
Kaizu et al[123] (Retro)	Bone	57	20-65 (mean 43) Gy	83.8% pain relief	6 mo

PR: Partial response; CR: Complete response; Retro: Retrospective study; LNs: Lymphnodes.

Table 2 Stereotactic body radiation therapy studies related to hepatocellular carcinoma, published the last five years

Ref.	Study design	Patient (n)	Median tumor size	Dose, No. of fractions	Median follow up (range), in months	Local control
Cárdenes et al[77]	Prosp	17	34 mL (8-95)	CP-A: 36-48 Gy/3 fr	24 (10-42)	100%
	Phase I			CP-B: 40 Gy/5 fr
Louis et al[72]	Retro	25	48 mL (7-363)	45 Gy/3 fr	12.7 (1-24)	95% (1 yr)
Kwon et al[79]	Retro	42	15 mL (3-82)	30-39 Gy/3 fr	28.7 (8.4-49.1)	72% (1 yr)
						67.5% (3 yr)
Seo et al[80]	Retro	38	40.5 mL (11-464)	33-57 Gy/3-4 fr	15 (3-27)	66% (2 yr)
Andolino et al[69]	Retro	60	29 mL (2-12)	CP-A: 44 Gy/3 fr	27 (2-52)	90 (2 yr)
			3.2 cm (1-6.5)	CP-B: 40 Gy/5 fr
Huang et al[81]	Retro	36	4.4 cm (1.1-12)	37 (25-48) Gy/4-5 fr	14 (2-35)	88% (1 yr)
						75% (2 yr)
Bae et al[82]	Retro	35	131 mL (21-2189)	45 (30-60) Gy/3-5 fr	14 (1-44)	69% (91 yr)
						51% (93 yr)
Bujold et al[78]	Prosp	102	117 mL (1-1913)	36 (24-54) Gy/6 fr	31 (2-36)	87% (1 yr)
	Phase I/II		7.2 cm (1.4-23.1)
Xi et al[90]	Retro	41	65 mL (± 48)	36 (30-48) Gy/6 fr	10 (4-25)	95%
Sanuki et al[127]	Retro	185	8 mL (1.5-65)	CP-A: 40 Gy/5 fr	24 (3-80)	91% (3 yr)
				CP-B: 35 Gy/5 fr

Prosp: Prospective; Retro: Retrospective; fr: Fraction; CP: Child-Pugh class of liver disease.